Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 23;12(11):988. doi: 10.1038/s41419-021-04268-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — A Bar graphs depicting the CSC fraction (ALDH^highCD44^high cells) in Cisplatin-naive and Cisplatin-resistant variants of UM-SCC-1, UM-SCC-22A, and UM-SCC-22B cells, as determined by flow cytometry. Graphs display mean ± SD (n = 3) and significance denoted by different lowercase letters at p < 0.05. B Western blottings showing baseline expression of phosphorylated STAT3, total STAT3, and Bmi-1 expression in Cisplatin-naive and Cisplatin-resistant HNSCC cell line variants. C Western blot analysis of Bmi-1 expression after treatment with rhIL-6 (20 ng/ml), Cisplatin (1 µm), and/or Tocilizumab (0.1 µM). D Representative images (×40) of Cisplatin-naive and Cisplatin-resistant UM-SCC-1 primary orospheres on day 8 after treatment with Cisplatin (1 µM) and/or Tocilizumab (0.1 µM). Cells were treated the day after seeding in ultra-low attachment plates. Inserts at ×100 magnification. E Bar graphs depicting number (mean ± SD) of primary orospheres per well, from three wells per experimental condition. Different lowercase letters indicate statistical significance at p < 0.05.